Document is current
Any future updates will be listed below
-
Authors
Coutinho, Frazer P.
Green, Colin R.
Acosta, Monica L.
Rupenthal, Ilva D.
-
Funding
Funding for this research was provided by:
Health Research Council of New Zealand ([13/692])
- License Information
-
More Information
Article History
First Online: 21 April 2020
Compliance with ethical standards
:
: C.R.G. is a founding scientist of OcuNexus Therapeutics, Inc. (USA) (and previously CoDa Therapeutics, Inc.) which has intellectual property related to the regulation of connexin channels in the treatment of ocular and other disease. F.P.C, C.R.G. and I.D.R. are inventors on a PCT application regarding Xentry fusion peptides for modulation of connexin gap junction and hemichannel activity, with this technology licenced by OcuNexus Therapeutics, Inc. (USA). M.L.A. declares no conflict of interest.
